Get the Stockscreener App
0.84
0.11%
-0.0009
After Hours:
.81
-0.03
-3.57%
Gossamer Bio Inc stock is traded at $0.84, with a volume of 846.49K.
It is down -0.11% in the last 24 hours and up +20.60% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
See More
Previous Close:
$0.8409
Open:
$0.83
24h Volume:
846.49K
Relative Volume:
0.65
Market Cap:
$190.35M
Revenue:
-
Net Income/Loss:
$-179.82M
P/E Ratio:
-0.3801
EPS:
-2.21
Net Cash Flow:
$-159.16M
1W Performance:
-9.68%
1M Performance:
+20.60%
6M Performance:
+47.76%
1Y Performance:
-1.44%
1-Day Range:
$0.7902
$0.8499
1-Week Range:
$0.76
$0.93
52-Week Range:
$0.4993
$1.60
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 922-0718
Address
3013 SCIENCE PARK, SAN DIEGO, CA
Compare GOSS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.84 | 190.35M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
The Manufacturers Life Insurance Company Boosts Stock Position in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
US Penny Stocks: 3 Picks With Market Caps Under $200M - Simply Wall St
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio - The Manila Times
XOMA Royalty Acquires Pulmokine for $20 Million Adding the - GlobeNewswire
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio - Benzinga
Gossamer Bio: Q3 Earnings Snapshot - Marketscreener.com
Adicet Bio Inc (NASDAQ: ACET) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register
GSA Capital Partners LLP Invests $67,000 in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Gossamer Bio Inc (GOSS)Monday, Aug 26, 2024 - Smartkarma
All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy - MSN
US Bancorp DE Makes New $39,000 Investment in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) - Yahoo Finance
Leerink Partnrs Raises Earnings Estimates for Gossamer Bio - Defense World
After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) - Yahoo Finance
HC Wainwright Increases Earnings Estimates for Gossamer Bio - MarketBeat
FMR LLC's Strategic Acquisition of Gossamer Bio Inc Shares - GuruFocus.com
Industry Analysts Just Made A Sizeable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Revenue Forecasts - Yahoo Finance
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Gossamer Bio Grants 183K Stock Options to New Hires at $0.88 Per Share | GOSS Stock News - StockTitan
Gossamer Bio (NASDAQ:GOSS) Earns Buy Rating from HC Wainwright - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Gossamer Bio Reports Revenue Growth Amid Strategic Collaborations - TipRanks
GOSSGossamer Bio, Inc. Latest Stock News & Market Updates - StockTitan
Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now - The Manila Times
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Sees Large Decline in Short Interest - Defense World
Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity - Yahoo Finance
3 US Penny Stocks With Market Caps Under $900M To Consider - Simply Wall St
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
It makes sense and dollars to buy Gossamer Bio Inc (GOSS) stock - SETE News
Financial Fitness Check: Examining Gossamer Bio Inc (GOSS)’s Key Ratios - The Dwinnex
Gossamer Bio Inc (GOSS) rating initates by Oppenheimer - Knox Daily
Millennium Management LLC Sells 898,042 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Sold by Millennium Management LLC - MarketBeat
The Attractiveness of Investing In Gossamer Bio Inc (GOSS) is Growing - Knox Daily
Investor’s Delight: Gossamer Bio Inc (GOSS) Closes Weak at 1.02, Down -2.86 - The Dwinnex
GOSS underperforms with a -2.86 decrease in share price - US Post News
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Gossamer Bio Inc [NASDAQ: GOSS] Sees Decrease in Stock Value - Knox Daily
Marshall Wace LLP Boosts Position in Gossamer Bio, Inc. (NASDAQ:GOSS) - MarketBeat
Several Insiders Invested In Gossamer Bio Flagging Positive News - Yahoo Finance
Analyzing Northwest Biotherapeutics (OTCMKTS:NWBO) and Gossamer Bio (NASDAQ:GOSS) - Defense World
Navigating GOSS’s Stock Market Maze: Ups and Downs in 2023 - The InvestChronicle
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. - Yahoo Finance
A better buy-in window may exist right now for Gossamer Bio Inc (GOSS) - SETE News
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 5.8% in September - Defense World
Analysts review Gossamer Bio Inc’s rating - Knox Daily
GOSS (Gossamer Bio Inc) has impressive results - US Post News
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gossamer Bio Inc Stock (GOSS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hasnain Faheem | President & CEO |
Jun 21 '24 |
Buy |
0.67 |
372,000 |
250,282 |
5,408,073 |
| Giraudo Bryan | COO/CFO |
Jun 18 '24 |
Buy |
0.59 |
100,000 |
59,110 |
480,010 |
| Smith Robert Paul JR | Chief Commercial Officer |
Jun 17 '24 |
Buy |
0.60 |
25,000 |
15,050 |
25,000 |
| Christian Waage | EVP, Tech Ops and Admin |
Mar 27 '24 |
Sale |
1.16 |
6,430 |
7,430 |
585,934 |
| Giraudo Bryan | COO/CFO |
Mar 27 '24 |
Sale |
1.16 |
6,430 |
7,431 |
92,737 |
| Hasnain Faheem | President & CEO |
Mar 27 '24 |
Sale |
1.16 |
23,172 |
26,773 |
120,293 |
| Aranda Richard | Chief Medical Officer |
Mar 18 '24 |
Sale |
1.33 |
4,018 |
5,342 |
198,799 |
| Peterson Caryn | EVP, Regulatory Affairs |
Mar 18 '24 |
Sale |
1.33 |
4,018 |
5,343 |
49,833 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):